MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12072-020-10097-z

Медицинская библиотека · Hepatology international · 2020

Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trial.

Li Xiaoke, Zhou Daqiao, Chi Xiaoling, Li Qin, Wang Li, Lu Bingjiu, Mao Dewen, Wu Qikai, Wang Xianbo, Zhang Mingxiang, Xue Jingdong, Li Yong, Lu Wei, Guo Jianchun, Jiang Feng, Zhang Xinwei, Li Zhiguo, Yang Xianzhao, Guo Hui, Gan Danan, He Liyun, Luo Lin, Zhang Ludan, Du Hongbo, Ye Yong'an

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПеревод в очереди

Аннотация

BACKGROUND AND AIM: Traditional Chinese medicine (TCM) is widely accepted and prescribed in China alongside Nucleoside analogs (NAs). In this double-blind, placebo-controlled, randomized, multi-center trial, we evaluated whether entecavir (ETV) plus TCM formulas Tiao-Gan-Yi-Pi granule (TGYP) and Tiao-Gan-Jian-Pi-Jie-Du granule (TGJPJD) increase the rate of hepatitis B e antigen (HBeAg) loss in Chinese patients.

METHODS

596 eligible participants were randomly assigned, in a 1:1 ratio, to two study groups in this 108-week trial: The experiment group was assigned ETV plus the TCM formula. The control group was assigned ETV plus a TCM placebo. We compared the rate of HBeAg loss by the end of week 108 between the two arms as the primary outcome. Secondary outcomes included hepatitis B surface antigen (HBsAg) level, proportion of undetectable HBV-DNA, and liver enzymes (ALT, AST, GGT) at week 108.

RESULTS

The combination therapy achieved superior HBeAg loss at 108 weeks, without additional adverse events. The rate of HBeAg loss at week 108 was 37.54% (95% CI 31.9-43.2%) in the experiment group and 27.21% (95% CI 22.0-32.4%) in the control group. There was a statistically significant difference between the two arms of 10.33% (95% CI 8.4-12.3%, p = 0.008). The DNA loss rate, serum HBsAg level, and liver enzymes were similar between the groups by the end of 108th week.

CONCLUSION

Combining the Chinese herbal formula with ETV therapy demonstrated superior HBeAg clearance compared with ETV monotherapy. This finding indicates that this combined therapy could produce an improved therapeutic effect and safety profile.

CLINICAL TRIAL NUMBER: ChiCTR-TRC-12002784 (Chinese Clinical Trial Registry).

Для цитирования: Li Xiaoke, Zhou Daqiao, Chi Xiaoling, Li Qin, Wang Li, Lu Bingjiu, Mao Dewen, Wu Qikai, Wang Xianbo, Zhang Mingxiang, Xue Jingdong, Li Yong, Lu Wei, Guo Jianchun, Jiang Feng, Zhang Xinwei, Li Zhiguo, Yang Xianzhao, Guo Hui, Gan Danan, He Liyun, Luo Lin, Zhang Ludan, Du Hongbo, Ye Yong'an. Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trial.. Hepatology international. 2020. DOI: 10.1007/s12072-020-10097-z.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.